Menu
← Oncology Approval Tracker
FDA DECISION ·
Polivy + bendamustine + rituximab product
polatuzumab vedotin-piiq + bendamustine + rituximab product · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with relapsed or refractory DLBCL not otherwise specified after at least two prior therapies, in combination with bendamustine and a rituximab product.
LAMPGEN ANALYSIS
Why it matters
This action converted the earlier accelerated later-line approval. FDA separately approved a first-line regimen on the same date.
What research teams should watch
Document prior lines and the correct treatment backbone when reconciling the two April decisions.
PRIMARY RECORDS